AEON Biopharma, Inc. (AEON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has a cash flow conversion efficiency ratio of 0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($-19.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is AEON Biopharma, Inc. worth for the company's overall valuation and market capitalisation.
AEON Biopharma, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
AEON Biopharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AEON Biopharma, Inc. ranked by their cash flow conversion efficiency. Explore AEON Biopharma, Inc. (AEON) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orange Minerals NL
AU:OMX
|
-0.043x |
|
Talisman Mining Ltd
AU:TLM
|
-0.083x |
|
Northern Graphite Corporation
V:NGC
|
0.021x |
|
IQ Group Holdings Bhd
KLSE:5107
|
0.086x |
|
AIRIQ INC.
F:EPXN
|
0.026x |
|
Real Heart
ST:HEART
|
-0.026x |
|
Nuvotec
KQ:060260
|
-0.075x |
|
NextPoint Capital SOCIMI S.A.
MC:YNPC
|
N/A |
Annual Cash Flow Conversion Efficiency for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of AEON Biopharma, Inc. from 2019 to 2024. View AEON live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-28.57 Million | $-20.29 Million | 0.710x | +127.30% |
| 2023-12-31 | $-153.04 Million | $-47.83 Million | 0.312x | +137.47% |
| 2022-12-31 | $-270.41 Million | $-35.58 Million | 0.132x | +3.59% |
| 2021-12-31 | $-223.82 Million | $-28.43 Million | 0.127x | +172.88% |
| 2020-12-31 | $-203.23 Million | $-9.46 Million | 0.047x | -93.14% |
| 2019-12-31 | $-65.87 Million | $-44.73 Million | 0.679x | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more